Yan Fang Liu | Senior Director, Epidemiology Lead for Asia Pacific
Johnson & Johnson | Singapore

Yan Fang Liu, Senior Director, Epidemiology Lead for Asia Pacific, Johnson & Johnson

Yanfang Liu, MD, MPH, is Senior Director of Epidemiology Asia Pacific at Janssen Research and Development based in Singapore.  She serves as Acting Chair and core member of Asia Pacific Protocol Review Committee for all the studies conducted by local and regional Medical Affairs and a co-leader of AP RWE taskforce at Janssen pharmaceutical companies of Johnson & Johnson. She has been a member of ISPE for the last 5 years, during which time she has been a reviewer for the abstracts submitted to the annual meetings.  She is an active member of AsPE and promotes the collaboration for utilizing the healthcare databases in Asia.  Together with other AsPE members, has published the article of “Databases in the Asia-Pacific Region The Potential for a Distributed Network Approach” at Epidemiology in 2015.    She also worked with Duke-NUS postgraduate medical school to provide lecture of Epidemiology and Observational Studies for the Joint Alliance DUKE-NUS Education (JADE) Certification Program to researchers, students, and pharmaceutical medical affairs.  She had collaborated with many academia and medical centers in Asia Pacific for over seventy observational studies in China, Japan, India, Australia, New Zealand, South Korea, Thailand, Singapore, Malaysia, Philippines, Vietnam, Indonesia, Bangladesh, and Taiwan.    Her research focuses on comparative effectiveness of medications/vaccines and post authorization safety study of mediations/vaccines, particularly in prostate cancer, multiple myeloma, B cell NHL, Inflammation Bowel Disease (IBD), Crohn’s Disease, Psoriasis, schizophrenia, pneumonia, gastroenteritis, hepatitis, acute otitis media, influenza, and vaccines.  Her expertise areas are in large, multiple country, prospective, observational, longitudinal studies in Asian countries, as well as utilizing large healthcare databases in Taiwan, South Korea, Australia and New Zealand.


Phar-East Day Two @ 15:55

Panel discussion: Using Real World Evidence (RWE) to support the rational use of medicine in Asia

  • Practicality issues in using RWE in Asia
  • Challenges and opportunities of regulatory innovation for SME pharma companies
  • RWE on emerging therapeutics: Key challenges and opportunities

back to speakers